

**SB 711 -1, -4, -7 STAFF MEASURE SUMMARY**

**Senate Committee On Health Care**

---

**Prepared By:** Brian Nieuburt, LPRO Analyst

**Meeting Dates:** 2/22, 3/29

---

**WHAT THE MEASURE DOES:**

Requires Oregon Health Authority to conduct study comparing the costs of pharmaceuticals used primarily by women to the costs of pharmaceuticals used primarily by men and the factors that contribute to any differences. Requires report to be delivered to Legislative Assembly by September 12, 2022 and include recommendations for legislative changes, if necessary, to address disparities in the costs of pharmaceuticals based on sex. Sunsets January 2, 2023. Takes effect on 91st day following adjournment sine die.

*REVENUE: May have revenue impact, but no statement yet issued.*

*FISCAL: May have fiscal impact, but no statement yet issued.*

**ISSUES DISCUSSED:**

**EFFECT OF AMENDMENT:**

- 1 Moves study responsibilities from Oregon Health Authority to Department of Consumer and Business Services as part of their prescription drug transparency program.
- 4 Limits study to disparities in the cost of hormone replacement drugs between those for men and those for women.
- 7 Moves study responsibilities from Oregon Health Authority to Department of Consumer and Business Services (DCBS) as part of their prescription drug transparency program. Requires DCBS to keep information strictly confidential.

**BACKGROUND:**

According to a 2019 Gallup study, the percentage of adults who reported not having had enough money in the past 12 months to "pay for needed medicine or drugs that a doctor prescribed" to them rose from 18.9 percent in January of that year to 22.9 percent in September. The study also revealed a widening gender gap of adults experiencing "medication insecurity," with a 27.5 percent among women compared to a 18.1 percent among men.

Senate Bill 711 requires the Oregon Health Authority to conduct a study comparing the costs of pharmaceuticals used primarily by women to the costs of pharmaceuticals used primarily by men and report the findings to the legislature by September 15, 2022.